Australia seems poised to welcome a groundbreaking medication for weight issues: Retatrutide. This new dual agonist – acting on both GLP-1 and GIP receptors – demonstrates promising efficacy in clinical research, indicating meaningful reductions in BMI. While availability is pending with the Therapeutic Goods Administration (TGA), a number of p… Read More